JAK1 inhibitors, for example, small molecule tofacitinib that inhibits JAK1 and JAK3, are used for treatment of rheumatoid arthritis and are currently tested in other immunological disorders, such as psoriasis and inflammatory bowel disease. This evidence concerns the gene JAK3 and rheumatoid arthritis.